文献速递产科

ARRIVE试验后产科实践与妊娠结局的变化

Changes in obstetrical practices and pregnancy outcomes following the ARRIVE trial.
PubMed 文献 · Am J Obstet Gynecol · 2022-02-06

基于美国出生数据库的回顾性队列研究,比较ARRIVE试验发表前后低风险初产妇的产科实践与围产结局。ARRIVE后组引产率升高(36.1% vs 30.2%)、39+6周前分娩率升高(42.8% vs 39.9%)、剖宫产率降低(27.3% vs 27.9%),但输血、ICU入住及新生儿辅助通气等不良结局小幅增加。

要点

  • ARRIVE试验发表后一年,引产率由30.2%升至36.1%,39+6周前分娩率由39.9%升至42.8%。
  • 剖宫产率由27.9%降至27.3%(调整OR 0.94 [0.93-0.94])。
  • 输血、母体ICU入住及新生儿辅助通气等不良结局小幅增加,需探索是否与产科实践变化相关。

核心结论

  • ARRIVE试验发表后一年,引产增多、39周分娩增多、剖宫产减少。
  • 部分母儿不良结局小幅但统计学显著增加,应探索其是否与同期产科实践变化相关。

研究设计与样本

  • 基于美国出生数据库的回顾性队列研究,纳入12周前开始产检、单胎、无畸形、≥39周分娩的低风险初产妇。
  • ARRIVE前组为2015年1月1日至2017年12月31日分娩者,共1,966,870例;ARRIVE后组为2019年1月1日至2019年12月31日分娩者,共609,322例;2018年出生者被排除。
  • 采用单因素和多因素分析,并用Cochran-Armitage趋势检验分析ARRIVE前组时间趋势。

主要发现

  • 调整混杂后,ARRIVE后组引产率36.1% vs ARRIVE前组30.2%(调整OR 1.36 [1.36-1.37])。
  • ARRIVE后组39+6周前分娩率42.8% vs ARRIVE前组39.9%(调整OR 1.14 [1.14-1.15])。
  • ARRIVE后组剖宫产率27.3% vs ARRIVE前组27.9%(调整OR 0.94 [0.93-0.94])。
  • ARRIVE后组输血率0.4% vs ARRIVE前组0.3%(调整OR 1.43 [1.36-1.50]),母体ICU入住率0.09% vs 0.08%(调整OR 1.20 [1.09-1.33])。
  • ARRIVE后组新生儿出生时辅助通气3.5% vs 2.8%(调整OR 1.28 [1.26-1.30]),>6小时辅助通气0.6% vs 0.5%(调整OR 1.36 [1.31-1.41]);5分钟APGAR<3为0.4% vs 0.3%(调整OR 0.91 [0.86-0.95]);NICU入住4.9% vs 4.9%(调整OR 1.01 [0.99-1.03])、新生儿惊厥0.04% vs 0.04%(调整OR 0.97 [0.84-1.13])、表面活性物质使用0.08% vs 0.07%(调整OR 1.05 [0.94-1.17])两组无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ARRIVE trial demonstrated the benefit of induction of labor at 39 weeks gestation. Obstetrics departments across the United States faced the challenge of adapting clinical practice in light of these data while managing logistical constraints. OBJECTIVE: To determine if there were changes in obstetrical practices and perinatal outcomes in the United States after the ARRIVE trial publication. STUDY DESIGN: This was a population-based retrospective cohort study of low-risk, nulliparous women who initiated prenatal care by 12 weeks gestation with singleton, nonanomalous pregnancies delivering at ≥39 weeks. Data were obtained from the US Natality database. The pre-ARRIVE group were women who delivered between January 1, 2015 and December 31, 2017. The post-ARRIVE group consisted of women who delivered between January 1, 2019 and December 31, 2019. Births that occurred in 2018 were excluded. Practice outcomes were rates of induction of labor, timing of delivery, and cesarean delivery rate. Adverse maternal outcomes were blood transfusion and admission to medical intensive care unit. Adverse neonatal outcomes were need for assisted ventilation (immediate and >6 hours), 5-minute APGAR score <3, neonatal intensive care unit admission, seizures, and surfactant use. Univariate and multivariate analyses were performed. Trends were tested across the time period represented by the pre-ARRIVE group using Cochran-Armitage trend test. RESULTS: There were 1,966,870 births in the pre-ARRIVE group and 609,322 in the post-ARRIVE group. The groups differed in age, race, body mass index, marital status, infertility treatment, and smoking history (P<.001). After adjusting for these differences, the post-ARRIVE group was more likely to undergo induction (36.1% vs 30.2%; adjusted odds ratio, 1.36 [1.36-1.37]) and deliver by 39+6 weeks of pregnancy (42.8% vs 39.9%; adjusted odds ratio, 1.14 [1.14-1.15]). The post-ARRIVE group had a significantly lower rate of cesarean delivery than the pre-ARRIVE group (27.3 % vs 27.9%; adjusted odds ratio, 0.94 [0.93-0.94]). Patients in the post-ARRIVE group were more likely to receive a blood transfusion (0.4% vs 0.3%; adjusted odds ratio, 1.43 [1.36-1.50]) and be admitted to medical intensive care unit (0.09% vs 0.08%; adjusted odds ratio, 1.20 [1.09-1.33]). Neonates in the post-ARRIVE group were more likely to need assisted ventilation at birth (3.5% vs 2.8%; adjusted odds ratio, 1.28 [1.26-1.30]) and >6 hours (0.6% vs 0.5%; adjusted odds ratio, 1.36 [1.31-1.41]). The neonates in the post-ARRIVE group were more likely to have low 5-minute APGAR scores (0.4% vs 0.3%; adjusted odds ratio, 0.91 [0.86-0.95]). Neonatal intensive care unit admission did not differ between the 2 groups (4.9% vs 4.9%; adjusted odds ratio, 1.01 [0.99-1.03]). There were no differences in neonatal seizures (0.04% vs 0.04%; adjusted odds ratio, 0.97 [0.84-1.13]), and surfactant use (0.08% vs 0.07%; adjusted odds ratio, 1.05 [0.94-1.17]) between the 2 groups. CONCLUSION: There were more inductions of labor, more deliveries at 39 weeks' gestation, and fewer cesarean deliveries in the year after the ARRIVE trial publication. The small but statistically significant increase in some adverse maternal and neonatal outcomes should be explored to determine if they are related with concurrent changes in obstetrical practices.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gilroy LC, Al-Kouatly HB, Minkoff HL, et al. Changes in obstetrical practices and pregnancy outcomes following the ARRIVE trial. Am J Obstet Gynecol. 2022. PMID: 35139334. doi:10.1016/j.ajog.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。